Volume : 13, Issue : 03, March – 2026
Title:
PHARMACOLOGICAL APPROACHES IN ALZHEIMER’S DISEASE: CURRENT THERAPEUTIC STRATEGIES AND FUTURE PERSPECTIVES
Authors :
Avishkar Bhimrao Khadatare,Vaibhavi Mohan Mane,Saniya Shivaji Kambale, Aarti baliram bansode , Dr.Rahul ishwara Jadhav
Abstract :
Alzheimer’s disease is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. The disease is characterized by progressive cognitive decline, memory impairment, and behavioral disturbances. The pathological hallmarks include amyloid-beta plaque deposition, tau protein hyperphosphorylation, oxidative stress, and neuroinflammation leading to neuronal degeneration. Current pharmacological treatments mainly aim to alleviate symptoms and slow disease progression. The most widely used drugs include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, along with the NMDA receptor antagonist memantine. In recent years, research has focused on disease-modifying therapies targeting amyloid-beta and tau proteins. Novel approaches including immunotherapy, anti-inflammatory drugs, antioxidants, gene therapy, and nanotechnology-based drug delivery systems are also being investigated. This review highlights the pathophysiology of Alzheimer’s disease, currently available pharmacological treatments, emerging therapeutic approaches, and future directions for improved management of this devastating disorder.
Keywords: Alzheimer’s disease, neurodegeneration, amyloid beta, cholinesterase inhibitors, memantine, pharmacotherapy.
Cite This Article:
Please cite this article in press Aarti baliram bansode et al., Pharmacological Approaches In Alzheimer’s Disease: Current Therapeutic Strategies And Future Perspectives., Indo Am. J. P. Sci, 2026; 13(03).
REFERENCES:
1. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2023.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease. Science. 2002.
3. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010.
4. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001.
5. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018.
6. Ballard C, Gauthier S. Alzheimer’s disease. Lancet. 2011.
7. Cummings J. Alzheimer’s disease drug development pipeline. Alzheimers Dement. 2022.
8. Scheltens P, et al. Alzheimer’s disease. Lancet. 2021.
9. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019.
10. Hampel H. The amyloid-beta pathway in Alzheimer’s disease. Nat Rev Neurol. 2021.
11. Wang JZ. Tau protein in Alzheimer’s disease. Neurosci Bull. 2013.
12. Butterfield DA. Oxidative stress in Alzheimer’s disease. Brain Res Bull. 2002.
13. Heneka MT. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015.
14. Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database. 2006.
15. Reisberg B. Memantine therapy in Alzheimer’s disease. N Engl J Med. 2003.
16. Sevigny J. Aducanumab reduces amyloid plaques. Nature. 2016.
17. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology. Cell. 2019.
18. Knopman DS. Alzheimer disease therapy and future directions. Nat Rev Neurol. 2021.
19. Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol. 2019.
20. Cummings JL. New therapeutic approaches for Alzheimer’s disease. Nat Rev Drug Discov. 2019.